Home Details
| Official Symbol of Gene | CCR5 |
| Species | Homo sapiens |
| Entrez Gene ID | 1234 |
| Official Full Name | C-C motif chemokine receptor 5 |
| Also known as | CKR5; CCR-5; CD195; CKR-5; CCCKR5; CMKBR5; IDDM22; CC-CKR-5 |
| Gene Type | protein coding |
| dbXrefs | Ensembl:ENSG00000160791 MIM:601373; AllianceGenome:HGNC:1606 |
| Map Location | 3p21.31 |
| Drug | Natalizumab |
| Interaction Type | inhibitor |
| Descent | mononuclear cells (PBMCs) and CSF surface cell molecules |
| Disease | MS |
| Pubmed ID | 17911462 |
| Year | 2007 |
| Title | Natalizumab in the Treatment of Patients with Multiple Sclerosis First Experience |
| Result | Natalizumab treatment alters the percentage of CCR5+ and CD4+ cells in CSF. In view of the excellent temporary clinical results of the therapy, which are yet to be assessed in the course of a longer time period, our results show a possible explanation for the therapeutic success of this drug as well as for the development of progressive multifocal leukoencephalopathy |
| Mechanism/pathway | CD4+ autoreactive T cells and their differentiation into Th1 phenotype are crucial events in the initial phases |

2023,CopyRight © HMU. College of Bioinformatics Science and Technology, Harbin, China.